Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript

Operator

Good morning, and welcome to the Equillium Virtual Investor Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Equillium website following the conclusion of the event.

I’d now like to turn the call over to your host, Stephen Connelly, Chief Scientific Officer at Equillium. Please go ahead.

Stephen Connelly
Chief Scientific Officer & President

Thanks, Tara, and good morning, everyone, and thanks for joining today’s webinar titled Insights to the Aryl Hydrocarbon Receptor and miR-124 Axis.

Now before we start, it probably makes sense to give you a little bit of context on this work from the outset, both the Aryl Hydrocarbon Receptor and miR-124 are two distinct biological molecules. And indeed, therapeutic strategies modulating both of them have been shown to be effective in treating ulcerative colitis. However, data exists from cells, animals and humans that point to a more direct and functional relationship between these two molecules. And despite the biological and therapeutic relevance, the paradoxical relationship between these two has remained elusive and controversial. So understanding this relationship has critically important implications for both mechanistic interpretation and rational development of therapies targeting the AhR/miR-124 Axis in inflammatory disease.

So presented here